Immunic receives USPTO allowance for vidofludimus calcium patent

Immunic announced that it has received a Notice of Allowance from the United States Patent and Trademark Office, or USPTO, for patent application 17/992,162, entitled, “Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases.” Specifically, the resulting patent covers dosing regimens associated with lead asset, vidofludimus calcium, or IMU-838, and other salt forms as well as free acid forms for the treatment of multiple sclerosis, or MS, including all regimens tested in the company’s MS clinical program. The patent is expected to provide protection into 2038, and, if additional Patent Term Extension is granted, may offer up to 14 years of market exclusivity in the United States upon the drug’s potential approval. The patent was previously granted to the company in Japan and certain other countries. This patent adds on the recently received notice of allowance for patent application 17/391,442, claiming treatment of relapsing MS, or RMS, with specific dose strengths.